Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.55 |
| ▸ | ITGAV | P06756 | 3/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191975 | 1.00 | CTSK (0.58) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL7370216 | 0.93 | CTSK (0.57) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL7370220 | 0.93 | CTSK (0.57) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL6560900 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL6560892 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL14844847 | 0.90 | ITGB3 (0.56) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL10561905 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL20364117 | 0.90 | LMNA (0.51) | CTSKCTSSCTSLCTSBLMNA | |
| SCHEMBL13139885 | 0.90 | LMNA (0.51) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL23574400 | 0.89 | CTSK (0.54) | CTSKCTSSCTSLCTSBITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2021256546-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | 味の素株式会社 | 2021-12-23 | — | — | WO | disclosed |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018045385-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2007027742-A2 | SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-03-08 | — | — | WO | disclosed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | CTSK 1072/4885CTSS 865/4885CTSL 156/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | CTSK 1072/4885CTSS 865/4885CTSL 156/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | CTSK 1072/4885CTSS 865/4885CTSL 156/4885 |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | CTSK 1072/4885CTSS 865/4885CTSL 156/4885 |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | CTSK 1072/4885CTSS 865/4885CTSL 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.